Nano-X Imaging Ltd. NNOX

Company Overview

Nano-X Imaging Ltd. is a medical imaging technology company focused on developing and commercializing digital X-ray systems and artificial intelligence-enabled radiology solutions. The company operates primarily in the healthcare technology and diagnostic imaging industries, with activities spanning imaging hardware, teleradiology services, and AI-assisted clinical workflow tools. Its core objective has been to lower the cost and improve accessibility of medical imaging through proprietary digital X-ray technology and cloud-based imaging infrastructure.

The company’s primary revenue drivers include imaging system commercialization efforts, teleradiology services, AI-based imaging analytics, and related healthcare software offerings. Nano-X has expanded beyond hardware through acquisitions and internal development, particularly in remote radiology interpretation and AI diagnostics. The company serves hospitals, imaging centers, healthcare providers, and underserved regions seeking lower-cost imaging alternatives. Nano-X was founded in Israel and later became publicly listed on the Nasdaq under the ticker NNOX. Its strategic positioning has centered on combining lower-cost imaging hardware with cloud connectivity and software-driven healthcare services to create an integrated imaging ecosystem.

Business Operations

Nano-X conducts operations through several major activities that include imaging hardware development, medical screening technologies, teleradiology, and AI-enabled diagnostic software. The company’s flagship imaging initiative has been the Nanox.ARC digital imaging system, which uses a proprietary cold cathode X-ray source technology intended to reduce system costs and broaden access to diagnostic imaging. Nano-X has also expanded its healthcare service capabilities through USARAD Holdings Inc., a teleradiology and radiology services provider acquired by the company, and through AI-focused assets including Zebra Medical Vision Ltd.

Revenue generation has historically come from radiology service operations, software solutions, and early commercialization activities tied to imaging systems and screening technologies. The company operates in both domestic and international markets, with development, engineering, and operational functions distributed across Israel, the United States, and additional regions. Nano-X has entered partnerships and distribution agreements in multiple countries to support future deployment of imaging systems and related healthcare services. Public filings and investor disclosures indicate that commercialization timelines for certain hardware technologies have evolved over time, with regulatory clearance and deployment milestones remaining important operational factors.

Strategic Position & Investments

Nano-X’s strategic direction has focused on building an integrated medical imaging platform that combines hardware, software, AI diagnostics, and remote healthcare services. A major component of this strategy has involved acquisitions intended to broaden the company’s capabilities beyond imaging equipment manufacturing. The acquisitions of Zebra Medical Vision Ltd. and USARAD Holdings Inc. significantly expanded the company’s AI analytics and teleradiology operations, positioning Nano-X within the broader digital healthcare and remote diagnostics markets.

The company has continued investing in imaging system development, cloud-enabled infrastructure, and AI-assisted clinical tools designed to support population health screening and diagnostic efficiency. Nano-X has also pursued international distribution arrangements and collaborations aimed at increasing adoption of its imaging technologies in emerging and underserved healthcare markets. Its strategic positioning emphasizes affordability and scalability in medical imaging, though the pace of widespread commercial adoption remains dependent on regulatory approvals, manufacturing execution, and healthcare provider adoption trends documented in public disclosures.

Geographic Footprint

Nano-X is headquartered in Israel, with substantial operational and commercial activities in the United States. The company maintains a global orientation, with partnerships, deployment initiatives, and distribution relationships spanning regions including North America, Europe, Asia, Africa, and parts of Latin America. Its business model has emphasized expanding access to imaging services in both developed and underserved healthcare markets.

The company’s acquisitions have also strengthened its international operational presence. Through USARAD Holdings Inc., Nano-X established a broader footprint in U.S.-based radiology services, while Zebra Medical Vision Ltd. added AI imaging expertise with international clinical integration opportunities. Public disclosures indicate ongoing efforts to establish commercial relationships and regulatory pathways across multiple jurisdictions, although market penetration levels vary by region and product category.

Leadership & Governance

Nano-X was co-founded by entrepreneurs and technology executives with backgrounds in medical imaging and healthcare innovation. The company’s leadership strategy has emphasized combining imaging hardware innovation with software-driven healthcare delivery models. Corporate governance is overseen by a board of directors and executive management team responsible for regulatory strategy, commercialization, AI integration, and global expansion initiatives.

Key executives have included:

• Erez Meltzer – Chairman of the Board
• Ran Poliakine – Founder and Executive Chairman (historically associated with company founding and strategic development)
• Erez Meltzer – Chief Executive Officer (following leadership transitions disclosed in public filings)
• Riki Assaf Harary – Chief Financial Officer
• Dagan Ben-Noon – Chief Executive Officer of Nanox AI
• Yehoshua Gleitman – President of Nanox AI (historically associated with AI operations)

The company’s leadership philosophy has focused on expanding accessibility to diagnostic imaging through lower-cost technology, cloud connectivity, and integrated healthcare services. Leadership commentary in public filings and investor materials has consistently emphasized global healthcare accessibility, preventive screening, and AI-enabled diagnostics as long-term strategic priorities.